Prime Medicine (PRME) Net Cash Flow (2021 - 2026)

Prime Medicine (PRME) has 6 years of Net Cash Flow data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 101.19% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$28.1 million (down 1537.11% YoY), and the FY2025 full-year result was -$119.8 million, down 184.69% from the prior year.
• Net Cash Flow for Q1 2026 stood at $1.1 million, up from -$8.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $139.7 million in Q4 2022 and bottomed at -$90.6 million in Q1 2025.
• The 5-year median for Net Cash Flow is -$12.9 million (2023), against an average of -$7.1 million.
• The widest annual swing landed in 2022, when Net Cash Flow soared 6691.46%; it then tumbled 272.28% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $139.7 million in 2022, then plunged by 101.71% to -$2.4 million in 2023, then surged by 2804.36% to $64.5 million in 2024, then tumbled by 112.97% to -$8.4 million in 2025, then jumped by 112.84% to $1.1 million in 2026.
• The last three Net Cash Flow figures came in at $1.1 million (Q1 2026), -$8.4 million (Q4 2025), and $17.6 million (Q3 2025), per Business Quant data.

Peer Comparison